Ensysce Biosciences (ENSCW) Cash from Financing Activities (2018 - 2025)

Ensysce Biosciences (ENSCW) has 8 years of Cash from Financing Activities data on file, last reported at $1.5 million in Q3 2025.

• Cash from Financing Activities for Q3 2025 came in at $1.5 million, down 64.86% year-over-year; the trailing twelve-month figure through Sep 2025 was $4.7 million (down 58.26% YoY), and the FY2024 annual result was $9.9 million, up 12.85% from the prior year.
• Cash from Financing Activities declined to $1.5 million in Q3 2025 per ENSCW's latest filing, from $1.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $9.2 million in Q4 2021 and troughed at -$391270.0 in Q1 2022.
• A 5-year average of $2.8 million and a median of $1.9 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 163.84% in 2022, then soared 4131.7% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $9.2 million in 2021, then tumbled by 78.88% to $1.9 million in 2022, then decreased by 24.7% to $1.5 million in 2023, then plunged by 92.3% to $112575.0 in 2024, then surged by 1189.33% to $1.5 million in 2025.
• Business Quant data shows ENSCW's Cash from Financing Activities at $1.5 million in Q3 2025, $1.9 million in Q2 2025, and $1.3 million in Q1 2025.